An experimental drug called daraxonrasib nearly doubled overall survival time for patients with inoperable pancreatic cancer in a late-stage clinical trial [2].
This result represents a significant shift in treating one of the deadliest forms of cancer. Because pancreatic tumors are often resistant to traditional therapies, a treatment that substantially extends life offers a critical new path for patients with limited options.
Developed by Mirati Therapeutics, daraxonrasib is a pan-RAS inhibitor. The drug targets the KRAS signaling pathway, which is a primary driver of tumor growth [1]. For decades, these specific mutations were considered "undruggable" by the medical community, making the development of a successful inhibitor a major technical milestone [1].
According to the trial data, KRAS mutations drive more than 90% of pancreatic cancer cases [1]. By blocking this pathway, daraxonrasib prevents the cancer cells from receiving the signals they need to multiply and spread.
The study was conducted across multiple oncology centers in the U.S. and Canada [2]. Researchers released the trial results in May 2024 [2]. The data indicated that the drug nearly doubled the overall survival time for the participants compared to previous benchmarks [2].
Medical professionals said the findings are a breakthrough treatment. While the drug remains experimental, the ability to effectively target the RAS protein provides a blueprint for treating other cancers driven by similar genetic mutations [3].
“Daraxonrasib nearly doubled overall survival time for patients with inoperable pancreatic cancer.”
The success of daraxonrasib signals a transition from broad chemotherapy toward precision medicine for pancreatic cancer. By successfully targeting the KRAS mutation—a long-standing obstacle in oncology—this treatment validates the pan-RAS inhibition approach, potentially opening the door for similar targeted therapies in other hard-to-treat solid tumors.
